July 10 (Reuters) - Prima Biomed Ltd PRR.AX
* Received regulatory and ethical approvals for clinical trial investigating IMP321 in new settings, called Insight
* Approval has been received from Paul-Ehrlich-Institut, Federal Institute For Vaccines And Biomedicines For German Federal Ministry Of Health Source text for Eikon: ID:nASX4BNC47 Further company coverage: PRR.AX